無料プレビュー

Denali Therapeutics Inc. (DNLI) · NASDAQ Global Select

プロフィール

Denali Therapeutics Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious neurological diseases using its proprietary TransportVehicle platform to deliver large-molecule biotherapeutics across the blood-brain barrier. The company develops enzyme replacement therapies for lysosomal storage diseases, oligonucleotide and antibody therapeutics for neurodegenerative diseases, and small-molecule inhibitors. Denali operates through partnerships with Biogen, Takeda, and Sanofi, with commercial activities primarily in the United States.

主要指標

株価: $19.14 (+2.52%)
時価総額: 30億ドル
PER（今期予想）: -8.4
PBR: 4.3
配当利回り: —
52週レンジ: $13.75 – $27.30
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09